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Stereoselective Synthesis of Protected Peptides Containing an 
anti b-Hydroxy Tyrosine 
Javier Fernández-Valparis,[a] Pedro Romea),*[a] and Fèlix Urpí*[a] 
Abstract: Protected peptides containing an anti b-hydroxy tyrosine 
are synthesized in a straightforward and highly efficient manner 
through the direct and stereoselective addition of N-azidoacetyl-4-
isopropyl-1,3-thiazolidine-2-thione to dialkyl acetals catalyzed by a 
nickel(II) complex, the forging of an amide bond by removal of the 
chiral auxiliary with an amino ester, and final coupling with a third 
amino acid. 
Introduction 
b-Hydroxy tyrosine is a nonproteinogenic amino acid present in 
a variety of cyclic peptides and depsipeptides[1] with remarkable 
biological activity such as vancomycin[2] or callipeltins[3] (Figure 
1). Obtaining these substrates thus requires the stereoselective 
synthesis and suitable protection of the desired b-hydroxy 
tyrosine stereoisomer[4–7] followed by the coupling with the other 
residues of the peptidic sequence. Notably, the latter step 
 
 
Figure 1. Metabolites containing an anti b-hydroxy tyrosine. 
often turns out to be troublesome and requires special and 
increasingly sophisticated coupling reagents[8] that permit the 
assembly of the different amino acids without causing 
epimerization of the Ca position or any other side reactions.[9] 
Thus, it goes without saying that if both the synthetic and the 
coupling steps could be merged in some way, the overall 
process would be much more efficient.  
Faced with this challenge, we envisaged that tripeptide 
fragments containing an anti b-alkoxy tyrosine might be 
prepared through (i) the direct and stereocontrolled reaction of 
chiral N-azidoacetyl-4-isopropyl-1,3-thiazolidine-2-thione with 
dialkyl acetals catalyzed by structurally simple and commercially 
available nickel(II) salts, and (ii) conversion of the resultant b-
alkoxy-a-azido adducts into the corresponding dipeptides by 
simple treatment with the appropriate a-amino acid (Scheme 
1).[10] Thereby, the 4-isopropyl-1,3-thiazolidine-2-thione[11,12] 
would act as a chiral template[13,14] but also as a coupling 
reagent.[15] In turn, (iii) reduction of the azido group followed by 
(iv) the forging of a further amide linkage would give the desired 
tripeptide in a straighforward, stereocontrolled, and highly 
efficient manner (Scheme 1). Herein, we disclose the 
implementation of such a strategy and its application to the 
synthesis of a protected tripeptide with a central allyl-protected 




Scheme 1. Retrosynthetic analysis of a protected tripeptide containing a 
central anti b-hydroxy tyrosine. 
Results and Discussion 
The azido group is currently considered as a masked amino 
group and has thus been exploited with a great success in a 
number of synthetic sequences. Unfortunately, metal enolates 
from a-azidocarbonyl compounds usually decompose into the 
corresponding imino derivatives, which prevent them from being 
used as surrogates for the amino acid glycine in the 
stereoselective construction of carbon-carbon bonds. As an 
exception, Franck found that treatment of chiral a-azidoacetyl 
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at low temperature afforded the corresponding titanium(IV) 
enolates, which underwent highly diastereoselective aldol 
reactions.[15a] More recently, Kumagai and Shibasaki have 
developed direct and asymmetric aldol and Mannich reactions 
from a-azido 7-azaindolinylamide catalyzed by a copper(I) 
complex.[6a,16] In turn, we have reported that chiral a-azidoacetyl 
thiazolidinethiones also participate in direct and stereoselective 
Lewis acid-mediated reactions with acetals catalyzed by 
nickel(II) complexes.[13] All together, these examples indicate 
that certain metal enolates of a-azido carboxylic compounds are 
stable enough to engage in the stereoselective construction of 
carbon–carbon bonds. 
Thus, taking advantage of these precedents, we carefully 
assessed the reaction of (S) N-azidoacetyl-4-isopropyl-1,3-
thiazolidine-2-thione (1 in Table 1)[12] with dialkyl acetals from 4-
alkoxybenzaldehydes (2–4 in Table 1). Following a 
comprehensive evaluation of the experimental conditions for 
such substrates, we firmly established that the reaction of 1 with 
1.1 equivalents of acetals 2–4 in the presence of 5 mol-% of 
commercially available and easy to handle (Me3P)2NiCl2, 1.5 
equivalents of TESOTf, and 1.5 equivalents of 2,6-lutidine at –
20 °C for 3 h provides the anti adducts 5–7 in high yields and 
diastereoselectivities (dr > 95:5). Importantly, the outcome of 
such reactions was highly reproducible in up to 6 mmol scale 
(entries 6–8 in Table 1), so adducts 5–7 may be prepared in a 
gram scale after a short chromatographic purification. 
Once we had reliable and efficient access to anti b-hydroxy 
tyrosine adducts, we next evaluated the removal of the chiral 
auxiliary.[15,17] As shown in Table 2, simple treatment of 5 with 
1.1 equivalents of hydrochloric salts of representative amino 
esters a–e afforded the desired dipeptides in up to 96% yield 
without epimerization (dr > 95:5) after a short chromatographic 
purification. 
Aiming to expand the scope of the process, we next examined 
the reaction with a-amino acids possessing a secondary amino 
group, like proline and pipecolic acid. Given that such reagents 
are less nucleophilic than their primary counterparts a–e, we first 
assessed the capability of methyl prolinate and pipecolate 
hydrochlorides (f and g respectively) to remove the chiral 
auxiliary of non–sterically hindered a-azidoacetyl 
thiazolidinethione 1 (Scheme 2). Gratifyingly, full conversion of 1 
was observed when it was treated with f under the experimental 
conditions previously optimized for a–e (see Table 2) and the 
expected amide 9f was isolated as a 5:1 mixture of rotamers 
with a 75% yield (Scheme 2). On the contrary, methyl pipecolate 
hydrochloride g turned out to be much less reactive and the 
displacement of the thiazolidinethione was incomplete after 4 h; 
thereby, amide 9g was also obtained as a 5:1 mixture of 
rotamers but in a moderate yield of 40% and a large amount 





Table 1. Direct, stereoselective, and catalytic reaction of 1 with dialkyl acetals from 4-alkoxybenzaldehydes[a] 
 
Entry Acetal R R1 Scale (mmol) Equiv TESOTf Time (h) Adduct dr[b] Yield[c] (%) 
1 2 Me Me 0.5 1.2 15 5 > 95:5 60 
2 2 Me Me 0.5 1.5 15 5 > 95:5 86 
3 2 Me Me 0.5 2.2 15 5 > 95:5 84 
4 2 Me Me 0.5 1.5 3 5 > 95:5 84 
5 3 Me Bn 0.5 1.5 15 6 > 95:5 83 
6 3 Me Bn 0.5 1.5 3 6 > 95:5 82 
7 3 Me Bn 3 1.5 3 6 > 95:5 81 
8 3 Me Bn 6 1.5 3 6 > 95:5 82 
9 4 Allyl Bn 0.5 1.5 15 7 > 95:5 74 
10 4 Allyl Bn 0.5 1.5 3 7 > 95:5 77 
11 4 Allyl Bn 1 1.5 3 7 > 95:5 76 
[a] The reaction was carried out from 1 (0.5 M in CH2Cl2), 2–4 (1.1 equiv), (Me3P)2NiCl2 (5 mol-%), and 2,6-lutidine (1.5 equiv). [b] Diastereomeric ratio 
established by 1H NMR analysis of the reaction mixture. [c] Yield of isolated product 
5 mol-% (Me3P)2NiCl2





















Table 2. Removal of the chiral auxiliary with amino esters. Synthesis of dipeptides [a] 
 
[a] The reaction was carried out from 5 (0.15 M in THF), a–e (1.1 equiv), and iPr2NEt (2 equiv) for 4 h. [b] Isolated yield. 
 
 
Scheme 2. Reaction of 1 with methyl L-prolinate (f) and L-pipecolate (g). 
Despite such preliminary results, a similar addition of methyl L-
prolinate (f) to adduct 5 from the dimethyl acetal of p-
anisaldehyde proved to be troublesome. Indeed, the same 
experimental conditions successfully applied to 1 afforded the 
desired dipeptide 8f with a meager 33% yield (entry 1 in Table 3). 
The yield was improved after stirring overnight at r.t. (entry 2 in 
Table 3), but longer reaction times did not produce any further 
increase. Other bases did not improve these results either 
(compare entries 2–4 in Table 3). In turn, acetonitrile proved to 
be less suitable than THF, whereas CH2Cl2 afforded similar 
results (entries 5 and 6 in Table 3). Finally, it was found that the 
reaction with the amino ester instead of the hydrochloride 
counterpart performed better and afforded dipeptide 8f as a 
single diastereomer (dr > 95:5) with a 69% yield after 4 h in the 
presence of 5 mol-% of DMAP or a 72% yield if 2.2 equivalents 
of methyl L-prolinate were used (entries 7 and 8 in Table 3).   
 
Table 3. Removal of the chiral auxiliary of 5 with methyl L-prolinate[a] 
 
Entry Solvent Base Time (h) Yield[b] (%) 
1 THF iPr2NEt 4 33 
2 THF iPr2NEt 16 58 
3 THF Et3N 16 40 
4 THF 2,6-lutidine 16 32 
5 CH3CN iPr2NEt 16 30 
6 CH2Cl2 iPr2NEt 16 60 
7[c] CH2Cl2 DMAP 4 69 
8[d] CH2Cl2 – 4 72 
[a] The reaction was carried out from 5 (0.15 M), methyl L-prolinate hydrochloride f (1.1 equiv), and base (2 equiv). [b] Yield of isolated 8f. [c] Methyl L-prolinate 
(1.1 equiv) and DMAP (5 mol-%) were used instead of f.  [d] Methyl L-prolinate (2.2 equiv) was used instead of f. 
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However, in spite of our efforts, the reaction of 5 with methyl L-
pipecolate (g) failed and the desired dipeptide was never 
isolated in synthetically useful yields. Likely, the steric hindrance 
of the substrate and the poor nucleophilic character of g prevent 
it from properly attacking the carbonyl bond of 5. 
Having established the scope of the process, we focused our 
attention on the synthesis of a peptidic fragment 10 structurally 
close to the east hemisphere of vancomycin (Figure 2) to test 
the potential of the method.  
 
 
Figure 2. Vancomycin-like tripeptide (10) containing a central protected anti 
b–hydroxy tyrosine. 
Application of the experimental conditions described in Table 2 
to the displacement of the chiral auxiliary from 7 with tert-butyl L-
asparaginate hydrochloride (i) gave dipeptide 11 as a single 
diastereomer (dr > 95:5) in an excellent 90% yield (Scheme 3). 
Then, reduction of the azido group with Me3P in THF/H2O 
produced the expected amino derivative,[18] which was 
immediately coupled to N-Fmoc-N-methyl-L-leucine with 
EDC·HCl and HOAt to afford fully protected tripeptide 12 with a 
78% two-step yield.[19] Finally, removal of the Fmoc protecting 
group with piperidine permitted us to isolate the desired 
tripeptide 10 with a 82% yield and a 94:6 diastereomeric ratio as 
established by HPLC. Therefore, protected tripeptide 10 has 
been synthesized in a straightforward manner through a four-
step sequence from a–azidoacetyl thiazolidinethione 1 with a 
43% overall yield. 
 
 
Scheme 3. Synthesis of a tripeptide containing a central anti b-hydroxy 
tyrosine. 
Conclusions 
In summary, Lewis acid-mediated additions of (S) N-azidoacetyl-
4-isopropyl-1,3-thiazolidine-2-thione (1) to dialkyl acetals of 4-
alkoxybenzaldehydes in the presence of 5 mol-% of 
commercially available and easy to handle (Me3P)2NiCl2 produce 
the corresponding anti adducts in high yields and 
diastereoselectivity. The smooth removal of the chiral auxiliary 
with a wide range of amino acids provide a variety of dipeptides, 
whose reduction and further coupling with a third amino acid 
give access to tripeptidic fragments containing a protected anti 
b-hydroxy tyrosine residue in a highly efficient manner. 
Experimental Section 
General: Unless otherwise noted, reactions were conducted in oven-
dried glassware under inert atmosphere of N2 with anhydrous solvents. 
The solvents and reagents were dried and purified when necessary 
according to standard procedures. Commercially available reagents were 
used as received.  Analytical thin-layer chromatography (TLC) was 
carried out on Merck silica gel 60 F254 plates and analyzed by UV (254 
nm) and stained with p-anisaldehyde; column chromatographies were 
carried under low pressure (flash) conditions and performed on SDS 
silica gel 60 (35–70 µm). Eluents are indicated in brackets in each case 
Rf values are approximate. HPLC analyses were conducted on a 
Shimadzu LC-20 HPLC system, using a C4 reverse phase column at a 
flow rate of 1 mL min–1 and detected at 220 nm. Melting points (Mp) were 






























































































dr 94:6   82%
1) Me3P, THF/H2O, r.t.
2) N-Fmoc-N-Me-Leu-OH










rotations ([a]D) were determined at 20 °C on a Perkin-Elmer 241 MC 
polarimeter equipped with a sodium lamp (l 589 nm, D-line). IR spectra 
(Attenuated Total Reflectance, ATR) were recorded on a Nicolet 6700 
FT-IR Thermo Scientific spectrometer and only the more representative 
frequencies (n) are reported in cm–1. 1H NMR (400 MHz) and 13C NMR 
(100.6 MHz) spectra were recorded at r.t. on a Varian Mercury 400. 
Chemical shifts (d) are quoted in ppm and referenced to internal TMS (d 
= 0.00 ppm for 1H NMR) and CDCl3 (d = 77.0 ppm for 13C NMR). Data 
are reported as follows: chemical shift (multiplicity, coupling constant(s), 
number of protons); multiplicity is reported as follows: s, singlet; d, 
doublet; t, triplet; q, quartet; m, multiplet (and their corresponding 
combinations); coupling constants (J) are quoted in Hz. Where necessary, 
2D techniques (NOESY, COSY, HSQC) were also used to assist on 
structure elucidation. High resolution mass spectra (HRMS) were 
obtained with an Agilent 1100 spectrometer by the Unitat 
d’Espectrometria de Masses, Universitat de Barcelona.  
General experimental procedure for the addition of 1 to dialkyl 
acetals: Solid (Me3P)2NiCl2 (7.0 mg, 25 µmol, 5 mol-%) was added to a 
solution of (S)-N-azidoacetyl-4-isopropyl-1,3-thiazolidine-2-thione (1, 122 
mg, 0.5 mmol) and the corresponding dialkyl acetal (2–4, 0.55 mmol) in 
CH2Cl2 (1.0 mL) under N2 at r.t. The resulting solution was cooled to –
20 °C. Then, TESOTf (170 µL, 0.75 mmol) and 2,6-lutidine (87 µL, 0.75 
mmol) were added dropwise after 3 and 7 min respectively and the 
reaction mixture was stirred at –20 °C for 3 h. The reaction mixture was 
quenched with sat NH4Cl (1.2 mL) and then diluted in H2O (20 mL). The 
aqueous layer was extracted with CH2Cl2 (3 × 20 mL). The combined 
organic extracts were washed with brine (50 mL), dried (MgSO4), and 
filtered. They were concentrated and filtered through a pad of silica gel 
(CH2Cl2); the solvent was removed in vacuo and the resultant oil was 
purified by column chromatography to afford the desired product 5–7.   
(S) N-[(2R,3R)-2-Azido-3-methoxy-3-(4-methoxyphenyl)propanoyl]-4-
isopropyl-1,3-thiazolidine-2-thione (5): The reaction was performed 
from 1 (122 mg, 0.5 mmol) and 4-methoxybenzaldehyde dimethyl acetal 
(2, 94 µL, 0.55 mmol) according to the general procedure to afford an 
anti/syn diastereomeric mixture (dr > 95:5 as established by 1H NMR 
analysis of the crude product). Purification of the crude product by 
column chromatography (CH2Cl2/hexanes 80:20) gave 166 mg (0.42 
mmol, 84% yield) of 5 as a yellow oil. Rf (CH2Cl2/hexanes 80:20) = 0.50. 
[a]D = +90.4 (c = 1.00, CHCl3). IR (ATR) n = 2960, 2824, 2095, 1686, 
1610, 1360, 1240, 1162 cm–1. 1H NMR (CDCl3, 400 MHz) d = 7.40–7.36 
(m, 2H), 6.96–6.93 (m, 2H), 6.50 (d, J = 9.0 Hz, 1H), 5.33 (ddd, J = 8.4, 
5.9, 1.6 Hz, 1H), 4.53 (d, J = 9.0 Hz, 1H), 3.83 (s, 3H), 3.42 (dd, J = 11.5, 
8.4 Hz, 1H), 3.15 (s, 3H), 3.05 (dd, J = 11.5, 1.6 Hz, 1H), 2.42–2.31 (m, 
1H), 1.10 (d, J = 6.8 Hz, 3H), 1.03 (d, J = 6.9 Hz, 3H) ppm. 13C NMR 
(CDCl3, 100.6 MHz) d = 203.1 (C), 170.5 (C), 160.2 (C), 129.2 (CH), 
129.1 (C), 114.1 (CH), 83.8 (CH), 71.8 (CH), 62.5 (CH), 56.5 (CH3), 55.3 
(CH3), 30.4 (CH2), 29.8 (CH), 18.9 (CH3), 17.3 (CH3) ppm. HRMS (+ESI): 
m/z calcd. for C16H19N4O2S2 [M – OMe]+: 363.0944; found: 363.0952. 
(S) N-[(2R,3R)-2-Azido-3-(4-benzyloxyphenyl)-3-methoxypropanoyl]-
4-isopropyl-1,3-thiazolidine-2-thione (6): The reaction was performed 
from 1 (1.47 g, 6.0 mmol), (Me3P)2NiCl2 (84.4 mg, 0.3 mmol, 5 mol-%), 
and 4-benzyloxybenzaldehyde dimethyl acetal (3, 1.70 g, 6.6 mmol) in 
CH2Cl2 (12 mL) under N2 at r.t. The resulting solution was cooled to –
20 °C. Then, TESOTf (2.0 mL, 9.0 mmol) and 2,6-lutidine (1.0 mL, 9.0 
mmol) were added dropwise after 3 and 7 min respectively and the 
reaction mixture was stirred at –20 °C for 3 h. Treatment of the reaction 
according to the general procedure afforded an anti/syn diastereomeric 
mixture (dr > 95:5 as established by 1H NMR analysis of the crude 
product). Purification of the crude product by column chromatography 
(CH2Cl2/hexanes 50:50) gave 2.30 g (4.9 mmol, 82% yield) of 6 as a 
yellow oil. Rf (CH2Cl2/Hexanes 50:50) = 0.30. [α]D = +91.4 (c = 2.0, 
CHCl3). IR (ATR) n = 2961, 2097, 1689, 1606, 1508, 1359, 1239, 1160 
cm–1. 1H NMR (CDCl3, 400 MHz) d = 7.45–7.31 (m, 7H), 7.04–7.00 (m, 
2H), 6.50 (d, J = 9.0 Hz, 1H), 5.33 (ddd, J = 8.0, 6.0, 1.6 Hz, 1H), 5.08 (s, 
2H), 4.53 (d, J = 9.0 Hz, 1H), 3.54 (dd, J = 11.5, 8.0 Hz, 1H), 3.15 (s, 3H), 
3.05 (dd, J = 11.5, 1.6 Hz, 1H), 2.41–2.32 (m, 1H), 1.10 (d, J = 6.8 Hz, 
3H), 1.03 (d, J = 6.9 Hz, 3H) ppm. 13C NMR (CDCl3, 100.6 MHz) d = 
203.1 (C), 170.5 (C), 159.4 (C), 136.8 (C), 129.4 (C), 129.3 (CH), 128.6 
(CH), 128.0 (CH), 127.5 (CH), 115.0 (CH), 83.8 (CH), 71.8 (CH), 70.0 
(CH2), 62.5 (CH), 56.6 (CH3), 30.4 (CH), 29.8 (CH2), 18.9 (CH3), 17.3 
(CH3) ppm. HRMS (+ESI): m/z calcd. for C22H23N4O2S2 [M – OMe]+: 
439.1257; found: 439.1253. 
(S) N-[(2R,3R)-3-Allyloxy-2-azido-3-(4-benzyloxyphenyl)propanoyl]-
4-isopropyl-1,3-thiazoli-dine-2-thione (7): The reaction was performed 
from 1 (244 mg, 1.0 mmol), (Me3P)2NiCl2 (14.1 mg, 50 µmol, 5 mol-%), 
and 4-benzyloxybenzaldehyde diallyl acetal (4, 341 mg, 1.1 mmol) in 
CH2Cl2 (2 mL) under N2 at r.t. The resulting solution was cooled to –20 °C. 
Then, TESOTf (340 µL, 1.5 mmol) and 2,6-lutidine (177 µL, 1.5 mmol) 
were added dropwise after 3 and 7 min respectively and the reaction 
mixture was stirred at –20 °C for 3 h. Treatment of the reaction according 
to the general procedure afforded an anti/syn diastereomeric mixture (dr 
> 95:5 as established by 1H NMR analysis of the crude product). 
Purification of the crude product by column chromatography (from 
CH2Cl2/hexanes 60:40 to 70:30) gave 337 mg (0.76 mmol, 76% yield) of 
7 as a yellow oil. Rf (CH2Cl2/Hexanes 60:40) = 0.30. [α]D = +123.0 (c = 
1.0, CHCl3). IR (ATR) n = 2962, 2872, 2105, 1692, 1608, 1509, 1362, 
1242, 1163 cm–1. 1H NMR (CDCl3, 400 MHz) d = 7.45–7.32 (m, 7H), 
7.03–7.00 (m, 2H), 6.49 (d, J = 9.0 Hz, 1H), 5.80–5.70 (m, 1H), 5.32 (ddd, 
J = 8.3, 6.0, 1.3 Hz, 1H), 5.18 (dq, J = 17.2, 1.7 Hz, 1H), 5.11–5.08 (m, 
1H), 5.08 (s, 2H), 4.74 (d, J = 9.0 Hz, 1H), 3.88 (ddt, J = 12.7, 4.9, 1.7 Hz, 
1H), 3.74 (ddt, J = 12.7, 6.2, 1.7 Hz, 1H), 3.54 (dd, J = 11.5, 8.3 Hz, 1H), 
3.04 (dd, J = 11.5, 1.3 Hz, 1H), 2.41–2.31 (m, 1H), 1.08 (d, J = 6.8 Hz, 
3H), 1.01 (d, J = 6.8 Hz, 3H) ppm. 13C NMR (CDCl3, 100.6 MHz) d = 
203.0 (C), 170.1 (C), 159.4 (C), 136.8 (C), 134.0 (CH), 129.6 (C), 129.3 
(CH), 128.6 (CH), 128.0 (CH), 127.5 (CH), 117.1 (CH2), 115.0 (CH), 81.0 
(CH), 71.8 (CH), 70.0 (CH2), 69.5 (CH2), 62.4 (CH), 30.5 (CH), 29.8 
(CH2), 19.1 (CH3), 17.5 (CH3) ppm. HRMS (+ESI): m/z calcd. for 
C22H23N4O2S2 [M – OAllyl]+: 439.1257; found: 439.1261. 
General experimental procedure for the removal of the chiral 
auxiliary of 5 with amino acids containing primary amino groups: 
Distilled iPr2NEt (2 equiv) was added to a mixture of the corresponding 
hydrochloride amino ester a–e (1.1 equiv) and 5 (1 equiv) in THF (0.15 
M) at 0 °C under N2. The reaction was stirred for 30 min at 0 °C and 4 h 
at r.t. The volatiles were evaporated. The crude mixture was diluted in 
CH2Cl2 (10 mL) and washed with 1 M NaOH (3 ´ 15 mL). The organic 
layer was dried (MgSO4), filtered, and concentrated. The resulting 
mixture was purified by column chromatography to afford the 
corresponding product. 
Displacement with methyl b-alaninate hydrochloride, 8a: The 
reaction was carried out according to the General Procedure from 5 (50 
mg, 127 µmol), a (20 mg, 143 µmol), and iPr2NEt (44 µL, 254 µmol). The 
purification of the crude mixture by column chromatography (from 
Hexanes/EtOAc 80:20 to 60:40) afforded 41 mg (121 µmol, dr > 95:5, 
96% yield) of methyl N-[(2R,3R)-2-azido-3-methoxy-3-(4-
methoxyphenyl)propanoyl]-b-alaninate (8a) as a yellowish oil. Rf 
(Hexanes/EtOAc 80:20) = 0.10. [α]D = –188.1 (c = 1.00, CHCl3). IR (ATR) 
n = 3330, 2950, 2106, 1732, 1663, 1511, 1246, 1172 cm–1. 1H NMR 
(CDCl3, 400 MHz) d = 7.24–7.22 (m, 2H), 6.87–6.84 (m, 2H), 6.57 (t (br), 
J = 5.5 Hz, 1H), 4.79 (d, J = 4.1 Hz, 1H), 4.32 (d, J = 4.1 Hz, 1H), 3.80 (s, 
3H), 3.61 (s, 3H), 3.47–3.39 (m, 1H), 3.30 (s, 3H), 3.27–3.21 (m, 1H), 
2.37 (ddd, J = 17.4, 6.3, 4.6 Hz, 1H), 2.19 (ddd, J = 17.4, 8.5, 4.9 Hz, 1H) 
ppm. 13C NMR (CDCl3, 100.6 MHz) d = 172.3 (C), 166.6 (C), 159.7 (C), 






129.0 (CH), 127.6 (C), 113.5 (CH), 83.6 (CH), 67.5 (CH), 56.8 (CH3), 
55.1 (CH3), 51.7 (CH3), 34.3 (CH2), 33.4 (CH2) ppm. HRMS (+ESI): m/z 
calcd. for C15H20N4NaO5 [M + Na]+: 359.1326; found: 359.1323. 
Displacement with methyl L-alaninate hydrochloride, 8b: The 
reaction was carried out according to the General Procedure from 5 (50 
mg, 127 µmol), b (20 mg, 143 µmol), and iPr2NEt (44 µL, 254 µmol). The 
purification of the crude mixture by column chromatography (from 
Hexanes/EtOAc 80:20 to 60:40) afforded 41 mg (121 µmol, dr > 95:5, 
96% yield) of methyl N-[(2R,3R)-2-azido-3-methoxy-3-(4-
methoxyphenyl)propanoyl]-L-alaninate (8b) as a yellowish oil. Rf 
(Hexanes/EtOAc 80:20) = 0.10. [α]D = –149.1 (c = 1.00, CHCl3). IR (ATR) 
n = 3309, 2937, 2104, 1740, 1661 1511, 1247, 1096 cm–1. 1H NMR 
(CDCl3, 400 MHz) d = 7.26–7.23 (m, 2H), 6.89–6.85 (m, 2H), 6.62 (d (br), 
J = 7.3 Hz, 1H), 4.75 (d, J = 4.5 Hz, 1H), 4.43 (quintet, J = 7.3 Hz, 1H), 
4.37 (d, J = 4.5 Hz, 1H), 3.81 (s, 3H), 3.65 (s, 3H), 3.31 (s, 3H), 1.35 (d, J 
= 7.3 Hz, 3H) ppm. 13C NMR (CDCl3, 100.6 MHz) d = 172.4 (C), 166.5 
(C), 159.9 (C), 129.0 (CH), 127.7 (C), 113.8 (CH), 83.6 (CH), 67.6 (CH), 
57.0 (CH3), 55.4 (CH3), 52.5 (CH3), 48.1 (CH), 18.5 (CH3) ppm. HRMS 
(+ESI): m/z calcd. for C15H20N4NaO5 [M + Na]+: 359.1326; found: 
359.1315. 
Displacement with methyl L-leucinate hydrochloride, 8c: The 
reaction was carried out according to the General Procedure from 5 (57 
mg, 144 µmol), c (28 mg, 154 µmol) and iPr2NEt (49 μL, 280 µmol). The 
purification of the crude mixture by column chromatography (from 
hexanes/EtOAc 85:15 to 50:50) afforded 51 mg (130 µmol, dr > 95:5, 
96% yield) of methyl (S)-N-[(2R,3R)-2-azido-3-methoxy-3-(4-
methoxyphenyl)propanoyl]-L-leucinate (8c) as a yellowish oil. Rf 
(hexanes/EtOAc 85:15) = 0.20. [α]D = –97.8 (c = 1.0, CHCl3). IR (ATR) n 
= 3308, 2954, 2104, 1743, 1660 1511, 1246, 1173 cm–1. 1H NMR (CDCl3, 
400 MHz) d = 7.26–7.22 (m, 2H), 6.89–6.85 (m, 2H), 6.42 (d, J = 8.4 Hz, 
1H), 4.73 (d, J = 4.7 Hz, 1H), 4.51 (td, J = 8.7, 5.1 Hz, 1H), 4.36 (d, J = 
4.7 Hz, 1H), 3.81 (s, 3H), 3.61 (s, 3H), 3.30 (s, 3H), 1.62–1.45 (m, 3H), 
0.92 (d, J = 6.1 Hz, 3H), 0.91 (d, J = 6.2 Hz, 3H) ppm. 13C NMR (CDCl3, 
100.6 MHz) d =172.2 (C), 166.7 (C), 159.9 (C), 129.0 (CH), 127.9 (C), 
113.8 (C, CH), 83.6 (CH), 67.6 (CH), 57.0 (CH3), 55.3 (CH3), 52.3 (CH3), 
50.7 (CH), 41.7 (CH2), 24.8 (CH), 22.9 (CH3), 22.0 (CH3) ppm. HRMS 
(+ESI): m/z calcd. for C18H27N4O5 [M + H]+: 379.1976; found: 379.1973. 
Displacement with methyl L-phenylalalinate hydrochloride, 8d: The 
reaction was carried out according to the General Procedure from 5 (50 
mg, 127 µmol), d (30 mg, 139 µmol) and iPr2NEt (44 μL, 254 µmol). The 
purification of the crude mixture by column chromatography (from 
Hexanes/EtOAc 80:20 to 60:40) afforded 45 mg (109 µmol, dr > 95:5, 
87% yield) of methyl N-[(2R,3R)-2-azido-3-methoxy-3-(4-
methoxyphenyl)propanoyl]-L-phenylalaninate (8d) as a yellowish solid. 
Mp = 103–105 °C. Rf (Hexanes/EtOAc 80:20 = 0.10). [α]D = –85.8 (c = 
1.00, CHCl3). IR (ATR) n = 3337, 2936, 2102, 1736, 1648, 1509, 1249, 
1100 cm–1. 1H NMR (CDCl3, 400 MHz) d = 7.30–7.20 (m, 5H), 7.09–7.05 
(m, 2H), 6.86–6.84 (m, 2H), 6.58 (d, J = 7.9 Hz, 1H), 4.73 (dt, J = 7.9, 6.0 
Hz, 1H), 4.67 (d, J = 4.9 Hz, 1H), 4.30 (d, J = 4.9 Hz, 1H), 3.79 (s, 3H), 
3.60 (s, 3H), 3.24 (s, 3H), 3.10 (dd, J = 13.9, 6.0 Hz, 1H), 3.01 (dd, J = 
13.9, 6.0 Hz, 1H) ppm. 13C NMR (CDCl3, 100.6 MHz) d = 170.8 (C), 
166.6 (C), 159.7 (C), 135.6 (C), 129.2 (CH), 128.8 (CH), 128.5 (CH), 
127.7 (C), 127.1 (CH), 113.6 (CH), 83.2 (CH), 67.4 (CH), 56.8 (CH3), 
55.2 (CH3), 53.1 (CH), 52.2 (CH3), 37.9 (CH2) ppm. HRMS (+ESI): m/z 
calcd. for C21H24N4NaO5 [M + Na]+: 435.1639; found: 435.1637. 
Displacement with methyl valinate hydrochloride, 8e: The reaction 
was carried out according to the General Procedure from 5 (59 mg, 150 
µmol), e (28 mg, 167 µmol) and iPr2NEt (52 μL, 0.3 mmol). The 
purification of the crude mixture by column chromatography (from 
Hexanes/EtOAc 85:15 to 70:30) afforded 47 mg (130 µmol, dr > 95:5, 
86% yield) of methyl N-[(2R,3R)-2-azido-3-methoxy-3-(4-
methoxyphenyl)propanoyl]-L-valinate (8e) as a yellowish oil. Rf 
(Hexanes/EtOAc 85:15) = 0.15. [α]D = –130.4 (c = 1.00, CHCl3). IR (ATR) 
n = 3325, 2960, 2102, 1703, 1663, 1511, 1208, 1098 cm–1. 1H NMR 
(CDCl3, 400 MHz) d = 7.26–7.19 (m, 2H), 6.89–6.86 (m, 2H), 6.51 (d, J = 
8.8 Hz, 1H), 4.70 (d, J = 5.0 Hz, 1H), 4.40 (dd, J = 8.8, 5.3 Hz, 1H), 4.36 
(d, J = 5.0 Hz, 1H), 3.81 (s, 3H), 3.62 (s, 3H), 3.30 (s, 3H),  2.12–2.04 (m, 
1H), 0.90 (d, J = 6.9 Hz, 3H), 0.86 (d, J = 6.9 Hz, 3H) ppm. 13C NMR 
(CDCl3, 100.6 MHz) d = 171.3 (C), 167.0 (C), 159.9 (C), 128.9 (CH), 
127.9 (C), 113.8 (CH), 83.6 (CH), 67.6 (CH), 57.2 (CH), 57.0 (CH3), 55.3 
(CH3), 52.1 (CH3), 31.6 (CH), 19.0 (CH3), 17.9 (CH3) ppm. HRMS (+ESI): 
m/z calcd. for C17H25N4O5 [M + H]+: 365.1819, found: 365.1820. 
Removal of the chiral auxiliary with amino acids containing 
secondary amino groups. 
Reaction of 1 with methyl L-prolinate hydrochloride. Synthesis of 9f: 
A mixture of 1 (122 mg, 0.5 mmol), methyl L-prolinate hydrochloride (91 
mg, 0.55 mmol), and iPr2NEt (174 μL, 1.0 mmol) in THF (2.5 mL) was 
stirred for 30 min at 0 °C and 4 h at r.t. under N2.The volatiles were 
evaporated. The crude mixture was diluted in CH2Cl2 (20 mL) and 
washed with 1 M NaOH (3 × 30 mL). The organic layer was dried 
(MgSO4), filtered, and concentrated. The resulting mixture was purified 
by column chromatography (from CH2Cl2 to CH2Cl2/EtOAc 90:10) to 
afford 79 mg (0.37 mmol, 75% yield) of methyl N-(2-azidoacetyl)-L-
prolinate (9f) as a 5:1 mixture of rotamers. Colorless oil. Rf (CH2Cl2) = 
0.10. [α]D = –114.2 (c = 1.00, CHCl3). IR (ATR) n = 2954, 2881, 2100, 
1737, 1651, 1436, 1170 cm–1. 1H NMR (CDCl3, 400 MHz) d = 4.56 (dd, J 
= 8.6, 3.7 Hz, 1H), 3.90 (s, 2H), 3.75 (s, 3H), 3.61–3.57 (m, 1H), 3.48–
3.42 (m, 1H), 2.28–2.00 (m, 4H) ppm. 13C NMR (CDCl3, 100.6 MHz) d = 
172.2 (C), 166.1 (C), 59.0 (CH), 52.4 (CH3), 50.9 (CH2), 46.3 (CH2), 29.0 
(CH2), 24.8 (CH2) ppm. HRMS (+ESI): m/z calcd. for C8H13N4O3 [M + H]+: 
213.0979, found: 213.0982. 
Reaction of 1 with methyl L-pipecolate hydrochloride. Synthesis of 
9g: A mixture of 1 (122 mg, 0.5 mmol), methyl L-pipecolate hydrochloride 
(99 mg, 0.55 mmol), and iPr2NEt (174 μL, 1.0 mmol) in THF (2.5 mL) was 
stirred for 30 min at 0 °C and 4 h at r.t. under N2. The volatiles were 
evaporated. The crude mixture was diluted in CH2Cl2 (20 mL) and 
washed with 1 M NaOH (3 × 30 mL). The organic layer was dried 
(MgSO4), filtered, and concentrated. The resulting mixture was purified 
by column chromatography (from CH2Cl2 to CH2Cl2/EtOAc 90:10) to 
afford 51 mg (0.21 mmol, 42% yield) of starting material 1 and 45 mg 
(0.20 mmol, 40% yield) of methyl N-(2-azidoacetyl)-L-pipecolate (9g) as 
a 5:1 mixture of rotamers. Colorless oil. Rf (CH2Cl2) = 0.10. [α]D = –77.7 
(c = 1.00, CHCl3). IR (ATR) n = 2946, 2102, 1735, 1651, 1445, 1204, 
1020 cm–1. 1H NMR (CDCl3, 400 MHz) d = 5.34 (d, J = 5.6 Hz, 1H), 3.99 
(s, 2H), 3.75 (s, 3H), 3.56–3.52 (m, 1H), 3.29 (td, J = 13.0, 3.0 Hz, 1H), 
3.33–3.27 (m, 1H), 1.77–1.64 (m, 3H), 1.50–1.32 (m, 2H) ppm. 13C NMR 
(CDCl3, 100.6 MHz) d = 171.4 (C), 167.4 (C), 52.5 (CH3), 52.4 (CH), 50.9 
(CH2), 43.1 (CH2), 26.7 (CH2), 25.2 (CH2), 20.9 (CH2) ppm. HRMS 
(+ESI): m/z calcd. for C9H15N4O3 [M+H]+: 227.1139; found: 227.1146. 
Reaction of 5 with methyl L-prolinate. Synthesis of 8f: A solution of 5 
(20 mg, 51 μmol) and methyl L-prolinate (14.4 mg, 112 μmol) in CH2Cl2 
(0.3 mL) was stirred a few minutes at 0 °C under N2 and 4 h at r.t. The 
volatiles were evaporated. The crude mixture was diluted in CH2Cl2 (5 
mL) and washed with 1 M NaOH (3 × 10 mL). The organic layer was 
dried (MgSO4), filtered, and concentrated. The resulting mixture was 
purified by column chromatography (Hexanes/EtOAc 80:20) to afford 13 
mg (36 µmol, dr > 95:5, 72% yield) of methyl N-[(2R,3R)-2-azido-3-
methoxy-3-(4-methoxyphenyl)-propanoyl]-L-prolinate (8f) as a yellowish 
oil. Rf (Hexanes/EtOAc 80:20) = 0.10. [α]D = –45.0 (c = 1.00, CHCl3). IR 
(ATR) n = 2952, 2100, 1741, 1650, 1511, 1433, 1247, 1172 cm–1. 1H 






NMR (CDCl3, 400 MHz) d = 7.34–7.30 (m, 2H), 6.96–6.92 (m, 2H), 4.59 
(dd, J = 8.4, 4.0 Hz, 1H), 4.54 (d, J = 9.3 Hz, 1H), 3.83 (d, J = 9.3 Hz, 
1H), 3.83 (s, 3H), 3.75 (s, 3H), 3.72–3.68 (m, 2H), 3.18 (s, 3H), 2.26–
2.20 (m, 1H), 2.13–1.97 (m, 3H) ppm. 13C NMR (CDCl3, 100.6 MHz) d = 
172.3 (C), 167.5 (C), 160.2 (C), 129.7 (C), 128.8 (CH), 114.3 (CH), 82.5 
(CH), 63.8 (CH), 59.3 (CH), 57.0 (CH3), 55.4 (CH3), 52.5 (CH3), 47.2 
(CH2), 29.3 (CH2), 24.9 (CH2) ppm. HRMS (+ESI): m/z calcd. for 
C17H23N4O5 [M+H]+: 363.1663, found: 363.1664. 
Synthesis of tripeptide 10. 
tert-Butyl N-[(2R,3R)-3-allyloxy-2-azido-3-(4-
benzyloxyphenyl)propanoyl]-L-asparaginate (11): Neat iPr2NEt (75 μL, 
430 μmol) was added to a solution of tert-butyl L-asparaginate 
hydrochloride (53 mg, 237 μmol) and 7 (107 mg, 215 μmol) in THF (1.5 
mL) at 0 °C under N2 and the resulting mixture was stirred for 4 h at r.t. 
The volatiles were evaporated. The residue was diluted in CH2Cl2 (5 mL) 
and washed with 1 M NaOH (3 ´ 10 mL). The organic layer was dried 
(MgSO4), filtered, and concentrated. Purification of the crude mixture by 
column chromatography (CH2Cl2/EtOAc 90:10 and then CH2Cl2/MeOH 
95:5) afforded 102 mg (195 µmol, dr > 95:5, 90% yield) of tert-butyl N-
[(2R,3R)-3-allyloxy-2-azido-3-(4-benzyloxyphenyl)propanoyl]-L-
asparaginate (11) as a yellow solid. Mp = 53–55 °C. Rf (CH2Cl2/MeOH 
95:5) = 0.30. [α]D = –81.6 (c 1.00, CHCl3). IR (ATR) n = 3343 (bs), 2978, 
2829, 2107, 1731, 1688, 1510, 1243, 1156 cm–1. 1H NMR (CDCl3, 400 
MHz) d = 7.44–7.31 (m, 5H), 7.29–7.25 (m, 2H), 7.21 (bd, J = 7.5 Hz, 1H), 
6.97–6.93 (m, 2H), 5.92–5.82 (m, 1H), 5.71 (bs, 1H), 5.45 (bs, 1H),  5.25 
(dq, J = 17.3, 1.7 Hz, 1H), 5.16 (dq, J = 10.5, 1.7 Hz, 1H), 5.04 (s, 2H), 
4.88 (d, J = 5.3 Hz, 1H), 4.49 (dt, J = 7.5, 4.9 Hz, 1H), 4.30 (d, J = 5.3 Hz, 
1H), 3.98 (ddt, J = 12.9, 4.7, 1.7 Hz, 1H), 3.84 (ddt, J = 12.9, 6.9, 1.7 Hz, 
1H), 2.75 (d, J = 4.9 Hz, 2H), 1.40 (s, 9H) ppm. 13C NMR (CDCl3, 100.6 
MHz) d = 171.6 (C), 168.9 (C), 167.0 (C), 159.1 (C), 136.8 (C), 134.0 
(CH), 129.0 (CH), 128.6 (CH), 128.4 (C), 128.0 (CH), 127.5 (CH), 117.0 
(CH2), 114.6 (CH), 82.6 (C), 80.8 (CH), 70.0 (CH2), 69.5 (CH2), 67.4 (CH), 
49.7 (CH), 37.4 (CH2), 27.8 (CH3) ppm. HRMS (+ESI): m/z calcd. for 
C27H33N5NaO6 [M + Na]+: 546.2323; found: 546.2332. 
N-Fmoc-N-Me-Leu-β-OAllyl-Tyr(Bn)-Asp(Ot-Bu) (12) 
Reduction of 11: A 1 M solution of Me3P in THF (367 μL, 367 μmol) was 
added to a solution of 11 (175 mg, 334 μmol) in 90:10 THF/H2O (2.6 mL) 
under N2 at r.t. and the resulting mixture was stirred fo 2 h. It was diluted 
in EtOAc (10 mL) and washed with H2O (3 ´ 15 mL). The organic layer 
was dried (MgSO4), filtered, and concentrated to afford 154 mg (309 
µmol, 93% yield) of the corresponding amino ester, which was used in 
the next step without further purification. Colorless solid. Mp = 51–53 °C. 
[α]D = +1.4 (c 1.00, CHCl3). IR (ATR) n = 3316 (bs), 2976, 2928, 1727, 
1661, 1508, 1220, 1153 cm–1. 1H NMR (CDCl3, 400 MHz) d = 7.79 (d, J = 
7.5 Hz, 1H), 7.44–7.31 (m, 5H), 7.25–7.22 (m, 2H), 6.97–6.93 (m, 2H), 
6.01 (bs, 1H), 5.93–5.83 (m, 1H), 5.48 (bs, 1H), 5.22 (dq, J = 17.2, 1.7 
Hz, 1H), 5.15 (dq, J = 10.4, 1.7 Hz, 1H), 5.04 (s, 2H), 4.74 (d, J = 5.8 Hz, 
1H), 4.59 (dt, J = 7.5, 5.1 Hz, 1H), 3.69 (d, J = 5.8 Hz, 1H), 3.98 (ddt, J = 
12.7, 5.1, 1.7 Hz, 1H), 3.84 (ddt, J = 12.7, 6.1, 1.7 Hz, 1H), 2.77 (d, J = 
5.1 Hz, 2H), 1.42 (s, 9H) ppm. 13C NMR (CDCl3, 100.6 MHz) d = 172.5 
(C), 171.8 (C), 169.5 (C), 158.8 (C), 136.9 (C), 134.4 (CH), 129.4 (C), 
128.9 (CH), 128.6 (CH), 128.0 (CH), 127.5 (CH), 117.1 (CH2), 114.7 
(CH), 82.4 (C), 81.3 (CH), 70.0 (CH2), 69.6 (CH2), 59.9 (CH), 49.5 (CH), 
37.9 (CH2), 27.8 (CH3) ppm. 
Coupling with N-Fmoc-N-methyl-L-leucine: A solution of N-Fmoc-N-
methyl-L-leucine (55 mg, 150 µmol) in CH2Cl2 (0.5 mL) was added via 
cannula to a solution of the abovementioned amino ester (51 mg, 100 
µmol), HOAt (45 mg, 330 µmol), and EDC·HCl (58 mg, 300 µmol) in 
CH2Cl2 (0.5 mL) under N2 at 0 °C. The resultant mixture was stirred for 1 
h at 0 °C and 15 h at r.t. The reaction was quenched with sat NaHCO3 (1 
mL), vigorously stirred for 15 min, and extracted with CH2Cl2 (3 ´ 10 mL). 
The organic extracts were washed with brine (30 mL), dried over MgSO4, 
filtered, and evaporated. Purification of the crude mixture by column 
chromatography (Hexanes/EtOAc 30:70, then CH2Cl2/MeOH 95:5) 
afforded 71 mg (84 µmol, 84% yield; 78% overall yield) of 12 as a 5:1 
mixture of rotamers. Colorless solid. Mp = 75–77 °C. Rf (CH2Cl2/MeOH 
95:5) = 0.32. [α]D = –32.0 (c 1.00, CHCl3). IR (ATR) n = 3303, 2928, 
1735, 1658 (bs), 1610, 1510, 1154 cm–1. 1H NMR (CDCl3, 400 MHz) d = 
7.77–7.75 (m, 2H), 7.60–7.57 (m, 2H), 7.41–7.21 (m, 13H), 6.93–6.91 
(m, 2H), 5.98–5.80 (m, 2H), 5.41 (bs, 1H), 5.21–5.16 (m, 1H), 5.14–5.11 
(m, 1H), 4.96 (s, 2H), 4.71–4.52 (m, 4H), 4.45–4.36 (m, 2H), 4.30–4.22 
(m, 1H), 3.95–3.87 (m, 1H), 3.81–3.73 (m, 1H), 2.78 (s, 3H), 2.76–2.72 
(m, 2H), 1.49–1.37 (m, 1H), 1.42 (s, 9H), 1.31–1.22 (m, 2H), 0.87–0.83 
(m, 6H) ppm. 13C NMR (CDCl3, 100.6 MHz) d = 171.6 (C), 170.6 (2 ´ C), 
169.2 (C), 159.0 (C), 157.1 (C), 143.8 (C), 141.3 (C), 136.8 (C), 134.0 
(CH), 129.2 (C), 128.7 (CH), 128.5 (CH), 128.0 (CH), 127.7 (CH), 127.5 
(CH), 127.1 (CH), 125.0 (CH), 120.0 (CH), 117.6 (CH2), 114.7 (CH), 82.5 
(C), 80.1 (CH), 69.9 (CH2), 69.8 (CH2), 67.9 (CH2), 57.4 (CH), 57.2 (CH), 
49.9 (CH), 47.2 (CH), 37.7 (CH2), 36.6 (CH2), 30.2 (CH3), 27.8 (CH3), 
24.6 (CH), 23.0 (CH3), 21.9 (CH3) ppm. HRMS (+ESI): m/z calcd. for 
C46H53N4O8 [M – OAllyl]+: 789.3858; found: 789.3853. 
H-N-Me-Leu-β-OAllyl-Tyr(Bn)-Asp(Ot-Bu) (10): A 10-% (v/v) solution of 
piperidine in CH2Cl2 (103 μL,104 μmol) was added to a solution of 12 (30 
mg, 35 μmol) in CH2Cl2 (0.4 mL) at 0 °C under N2 and the resulting 
mixture was stirred for one day at r.t. The volatiles were evaporated. 
Purification of the residue by column chromatography (from 
CH2Cl2/MeOH 95:5 to 90:10) afforded 19 mg (30 µmol, 82% yield) of a 
94:6 diastereomeric mixture (HPLC analysis) of tripeptide 10 as a 
colorless solid. Mp = 180–182 °C. Rf (CH2Cl2/MeOH 95:5) = 0.13. HPLC 
(C4 reverse phase column, from 30% to 40% of CH3CN in H2O, 1 mL/min, 
220 nm), tR = 7.02 min. [α]D = –16.1 (c 1.00, CHCl3). IR (ATR) n = 3286, 
2924, 2853, 1733, 1656 (bs), 1510, 1242, 1157 cm–1. 1H NMR (CDCl3, 
400 MHz) d = 7.62 (bs, 1H), 7.43–7.22 (m, 8H), 6.96–6.93 (m, 2H), 6.06 
(bs, 1H), 5.90–5.81 (m, 1H), 5.51 (bs, 2H), 5.22 (dd, J = 17.2, 1.6 Hz, 1H), 
5.15 (dq, J = 10.4, 1.6 Hz, 1H), 5.04 (s, 2H), 4.75–4.71 (m, 2H), 4.67–
4.62 (m, 1H), 3.93 (dd, J = 12.8, 5.1 Hz, 1H), 3.81 (ddt, J = 12.8, 6.5 Hz, 
1H), 2.88–2.84 (m, 1H), 2.77 (d, J = 4.5 Hz, 2H), 2.12 (s, 3H), 1.49–1.37 
(m, 1H), 1.45 (s, 9H), 1.31–1.22 (m, 2H), 0.86 (d, J = 9.2 Hz, 3H), 0.84 (d, 
J = 9.1 Hz, 3H) ppm. 13C NMR (CDCl3, 100.6 MHz) d = 171.7 (C), 169.6 
(2 ´ C), 169.2 (C), 159.0 (C), 136.8 (C), 134.2 (CH), 129.4 (C), 128.9 
(CH), 128.6 (CH), 128.0 (CH), 127.5 (CH), 117.4 (CH2), 114.8 (CH), 82.6 
(C), 79.9 (CH), 70.0 (CH2), 69.7 (CH2), 63.1 (CH), 57.1 (CH), 49.8 (CH), 
42.4 (CH2), 37.9 (CH2), 35.0 (CH3), 27.9 (CH3), 25.0 (CH), 23.0 (CH3), 
21.9 (CH3) ppm. HRMS (+ESI): m/z calcd. for C34H49N4O7 [M + H]+: 
625.3596; found: 625.3591. 
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